期刊文献+

缬沙坦对原发性高血压合并糖尿病患者血压及肾功能影响的研究 被引量:7

Influence of valsartan on blood pressure and renal function in patients with essential hypertension complicated with diabetes
下载PDF
导出
摘要 目的探讨缬沙坦在原发性高血压合并糖尿病治疗中的作用。方法原发性高血压合并糖尿病患者40例随机分为治疗组(20例)和对照组(20例)。治疗组口服雷米普利联合缬沙坦;对照组口服雷米普利,2组均治疗24周。观察2组治疗后的降压疗效、24 h尿蛋白、血尿素氮(BUN)、血肌酐(SCr)等指标的变化情况。结果治疗组降压总有效率为75.0%,高于对照组降压总有效率(70.0%),但差异无统计学意义(P>0.05)。2组治疗后24 h尿蛋白水平均较治疗前明显降低,治疗组降低水平较对照组更加明显。结论缬沙坦治疗原发性高血压合并糖尿病安全有效,更有利于保护肾脏功能。 Objective To investigate the role of valsartan in the treatment of primary hypertension complicated with diabetes.Methods Forty patients with essential hypertension complicated with diabetes were randomly divided into treatment group(n=20) and control group(n=20).The treatment group was administered ramipril combined with valsartan while the control group only ramipril.Both groups were treated for 24 weeks.After treatment,the changes of the antihypertensive efficacy,24 h urinary protein,blood urea nitrogen(BUN),and serum creatinine(SCr) in both groups were observed.Results The overall antihypertensive efficacy rate(75.0%) was higher in the treatment group than that(70.0%)in the control group,but the difference was not statistically significant(P〉0.05).After treatment,24 h urinary protein level was significantly lower in both groups.But compared with the control group,the treatment group had more significant decrease.Conclusion The valsartan treatment for hypertension complicated with diabetes is safe and effective.It can better protect renal function.
作者 马美林
出处 《实用临床医药杂志》 CAS 2012年第11期93-95,共3页 Journal of Clinical Medicine in Practice
关键词 缬沙坦 高血压 糖尿病 平均动脉压 尿蛋白 valsartan; hypertension; diabetes; mean arterial pressure; urinary protein
  • 相关文献

参考文献9

  • 1Suzuki K, Aizawa Y. Evaluation of dosing time - related anti - hypertensive efficacy of valsartan in patients with type 2 di- abetes[J].Clin Exp Hypertens, 2011, 33(1): 56.
  • 2Luan FL. Effect of valsartan on the incidence of diabetes[J]. N Engl J Med, 2010, 363(8) : 792.
  • 3Kintscher U, Marx N, Martus P, et al. Effect of high- dose valsartan on inflammatory and lipid parameters in pa- tients with Type 2 diabetes and hypertension [J] Diabetes Res Clin Pract, 2010, 89(3) : 209.
  • 4杨坚,赵旭燕.缬沙坦对2型糖尿病合并原发性高血压患者血压、C反应蛋白和尿微量白蛋白的影响[J].武警医学,2010,21(3):246-247. 被引量:2
  • 5曹桂秋,汤宝鹏,韩伟,李晋新.缬沙坦对高血压合并糖尿病患者血压及血管内皮功能的影响[J].新疆医科大学学报,2005,28(9):835-837. 被引量:3
  • 6Lee JM, Kim JH, Son HS, et al. Valsartan increases circu- lating adiponectin levels without changing HOMA IR in pa- tients with type 2 diabetes mellitus and hypertension[J]. J Int Med Res, 2010, 38(1): 234.
  • 7Weir MR, Hollenberg NK, Zappe DH, et al. Antihyperten- sive effects of double the maximum dose of valsartan in African - American patients with type 2 diabetes mellitus and albuminuria[J] J Hypertens, 2010, 28 ( 1 ) : 186.
  • 8Van der Niepen P, Woestertburg A, Bri H, et al. Effective- ness of valsartan for treatment of hypertension: patient profil- ing and hierarchical modeling of determinants and outcomes (the PREVIEW study) [J]. Ann Phamaacother, 2009, 43 (5) : 849.
  • 9Beloumv IuB, Shestakova MV, Belousov DIu. Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus[J]. Kardiologiia, 2008, 48(12) : 14.

二级参考文献17

  • 1Gabir M M,Hanson R L,Dabelea D,et al.The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes[J].Diabetes care,2000,23(8):1108-1112.
  • 2Guidelines set new definitions.Update treatment for hypertension[J].Bull world health organ,1999,77(3):293.
  • 3Tuttle K R.Linking metabolism and immunologg:diabetic nephropa2thy is an inflammatory disease[J].J Am Soc Nephrol,2005,16 (6):1537-1538.
  • 4Pitsavos C,Chrysohoou C,Panagiotakos D B,et al.Abdominal obesity and inflammation predicts hypertension among prehypertensive men and women:the ATTICA Study[J].Heart vessels,2008,23(2):96-103.
  • 5Sesso H D,Wang L,Buring J E,et al.Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women[J].Am J Hypertension,2007,49(2):304-310.
  • 6Pradhan A D,Cook N R,Buring J E,et al.C-reactive protein is independently associated with fasting insulin in nondiabetic women[J].Arterioscler Thromb Vasc Biol,2003,23:650-655.
  • 7Hunyady L,Catt K J.Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II[J].Mol Endocrinol,2006,20:953-997.
  • 8Michael P, Malte K, Peter R, et al. Additive effect of coexistent type 2 diabetes and arterial hypertension on endothelial dysfunction in resistance arteries of forearm vascular[J]. Angiology,2000, 51(7):545-554.
  • 9Cheetham C, Collis J, O′Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes[J]. J Am Coll Cardiol, 2000, 36(5):1461-1466.
  • 10Kalinowski L, Matys T, Chabielska E, et al. Angiotensin Ⅱ AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release[J]. Hypertension, 2002, 40(4):521-527.

共引文献3

同被引文献46

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部